Skip to main content
WVE
NASDAQ Life Sciences

WVE-006 Achieves MZ-Like Phenotype in AATD Trial; FDA Accelerated Approval Pathway Expected Mid-2026

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$6.58
Mkt Cap
$1.231B
52W Low
$5.02
52W High
$21.73
52W Position info
31% above low
Off High info
70% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

WVE sits 31% above its 52-week low of $5.02.

Summary

Wave Life Sciences announced strong clinical data for WVE-006 in AATD, showing significant efficacy and safety, and expects to discuss an accelerated approval pathway with the FDA by mid-2026.


Key Events · Product Development and Regulatory · WVE

  • Positive WVE-006 Clinical Data

    Updated Phase 1b/2a data for WVE-006 in AATD showed achievement of an MZ-like phenotype, 71% reduction in harmful Z-AAT, and restoration of wild-type M-AAT.

  • Restored Dynamic AAT Production

    WVE-006 treatment restored the ability to dynamically produce AAT protein during acute phase responses, a critical protective mechanism for the lungs.

  • Favorable Safety and Dosing

    The drug was well tolerated with no liver toxicities, and data supports convenient monthly subcutaneous dosing with sustained effects for at least three months.

  • Potential Accelerated Approval Pathway

    The company expects to receive regulatory feedback from the FDA on a potential accelerated approval pathway for WVE-006 by mid-2026.


Analysis · WVE · Life Sciences

Wave Life Sciences reported highly positive updated Phase 1b/2a clinical data for WVE-006 in alpha-1 antitrypsin deficiency (AATD), demonstrating the drug's ability to achieve an MZ-like phenotype, significantly reduce harmful Z-AAT, and restore dynamic M-AAT production. The data supports convenient monthly dosing and a favorable safety profile. This strong clinical validation, coupled with anticipated FDA feedback on a potential accelerated approval pathway by mid-2026, significantly de-risks the program and could lead to a new standard of care for AATD, addressing both lung and liver manifestations.

How filings like this one have moved

In the 30 days to Nov 8, 2026, 51% of the 200 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.88%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, WVE was trading at $6.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $5.02 to $21.73. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

WVE - Latest Insights

WVE
Oct 27, 2026, 7:50 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.42
Real-time Price: $3.34 info
Change: -$0.080 (-2%) info
Market Cap: $663.675M info
WVE
Oct 27, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.45
Real-time Price: $3.34 info
Change: -$0.110 (-3%) info
Market Cap: $663.675M info
WVE
Oct 01, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.71
Real-time Price: $3.34 info
Change: -$0.370 (-10%) info
Market Cap: $663.675M info
WVE
Sep 23, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.50
Real-time Price: $3.34 info
Change: -$1.16 (-26%) info
Market Cap: $663.675M info
WVE
Aug 07, 2026, 4:52 PM EDT
Filing Type: 8-K12B
Importance Score:
7
Price at Filing: $6.14
Real-time Price: $3.34 info
Change: -$2.80 (-46%) info
Market Cap: $663.675M info